期刊文献+

帕金森病药物治疗的研究进展 被引量:12

Progress in Research on Drug Therapy for Parkinson’s Disease
下载PDF
导出
摘要 帕金森病(Parkinson’s disease,PD)是一种常见于中老年人缓慢进展的神经系统变性疾病,临床表现主要包括静止性震颤、运动迟缓、肌强直和姿势步态异常等运动障碍,同时伴有一些非运动症状,显著降低了患者的生活质量,给家庭及社会带来了极大的负担。随着医学的发展,人们对帕金森病的发病机制逐渐认识,其治疗方法层出不穷,但目前国内外PD的治疗仍以药物为主。就国内外帕金森病常见的药物治疗的最新进展进行综述,以期为广大临床医生在帕金森病药物治疗方面提供一些帮助。 Parkinson’s disease(PD) is a slow-developing central nervous system degenerative disease common in middle-aged and elderly people. It mainly causes dyskinesia such as resting tremor, muscle rigidity, bradykinesia and abnormal posture gait. There are some non-motor symptoms that significantly reduce the quality of life of patients and bring a great burden on families and society. With the development of medicine, people gradually understand the pathogenesis of Parkinson’s disease, and its treatment methods are endless, but at present, the treatment of PD at home and abroad is still based on drugs. This article reviews the recent advances in drug therapy for Parkinson’s disease at home and abroad, with a view to providing some clinicians with some help in the treatment of Parkinson’s disease.
作者 苏红军 SU Hongjun(Department of Neurology,Baodi District People's Hospital,Tianjin 301800,China)
出处 《继续医学教育》 2020年第2期148-151,共4页 Continuing Medical Education
关键词 帕金森病 震颤 多巴胺 药物治疗 单胺氧化酶抑制 研究进展 Parkinson’s disease tremor dopamine drug therapy monoamine oxidase inhibition research progress
  • 相关文献

参考文献8

二级参考文献82

  • 1邹海强,马敬红.帕金森病轻度认知功能障碍的诊断标准:运动障碍协会工作组指南[J].中华临床医师杂志(电子版),2012,6(19):6013-6017. 被引量:27
  • 2Tang B Xiong H Sun P Zhang Y Wang D Hu Z Zhu Z Ma H Pan Q Xia JH Xia K Zhang Z.Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease[J].中国生物学文摘,2006,20(8):16-16. 被引量:30
  • 3袁莉娟,纪立伟.抗帕金森病药物恩他卡朋的药理作用与临床评价[J].中国新药杂志,2007,16(2):171-174. 被引量:5
  • 4LARRAMENDY C, TARAVINI IRE, SABORIDO MD, et al. Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism[ J]. Behav Brain Res, 2008,194 ( 1 ) :44 - 51. 被引量:1
  • 5CHEN L, TOGASAKI DM, LANGSTON JW, et al. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA treated dyskinetic monkeys [ J ]. Neurosci, 2005,132 ( 2 ) : 409 - 420. 被引量:1
  • 6NUTT JG, OBESO JA, STOCCHI F. Continuous dopamine-re- ceptor stimulation in advanced Parkinson's disease [ J]. Trends Neurosci, 2000, 23(10S) :S109 - 115. 被引量:1
  • 7SUJITH OK, LANE C. Review: Therapeutic options for continu- ous dopaminergic stimulation in Parkinson's disease [ J]. Thera- peutic Advances in Neurological Disorders, 2009, 2(2 ):105-113. 被引量:1
  • 8SCHWARZ BIOSCIENCES. Pharmacology Reviews, NEUPRO, NDA 021829. http://www. accessdata. fda. gov/drugsatfda docs/nda/2007/021829s000_PharmR P2a. pdf. 2006, 196- 198. 被引量:1
  • 9BELLUZZI JD, DOMINO EF, MAY JM, et al. N-0923, a selec- tive dopamiue D2 receptor agonist, is efficacious in rat and mon- key models of Parkinson's disease [ J ]. Mov Disord, 1994,9 ( 2 ) : 147 - 154. 被引量:1
  • 10ROSE S, SCHELLER DK, BREIDENBACH A, et al. Plas- ma levels of rotigotine and the reversal of motor deficits in MPTP- treated primates[ J]. Behav Pharmacol, 2007, 18(2) :155 - 160. 被引量:1

共引文献188

同被引文献135

引证文献12

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部